Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)

NCT01738191 is registered in ClinicalTrials.gov with Medical University of South Carolina as lead sponsor.

NCT NCT01738191
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01738191 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Atomoxetine Treatment for Cognitive Impairment in Parkinson's Disease (ATM-Cog)
Lead sponsor
Medical University of South Carolina
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2012
Completion date
August 31, 2014
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cognitive impairment, parkinson's disease